细胞角蛋白及波形蛋白在原发性肺肉瘤样癌中的诊断价值及其与临床预后的关系

陶慧峰, 吴庆国, 张晓林, 潘磊, 李锋

陶慧峰, 吴庆国, 张晓林, 潘磊, 李锋. 细胞角蛋白及波形蛋白在原发性肺肉瘤样癌中的诊断价值及其与临床预后的关系[J]. 实用临床医药杂志, 2020, 24(8): 36-40. DOI: 10.7619/jcmp.202008010
引用本文: 陶慧峰, 吴庆国, 张晓林, 潘磊, 李锋. 细胞角蛋白及波形蛋白在原发性肺肉瘤样癌中的诊断价值及其与临床预后的关系[J]. 实用临床医药杂志, 2020, 24(8): 36-40. DOI: 10.7619/jcmp.202008010
TAO Huifeng, WU Qingguo, ZHANG Xiaolin, PAN Lei, LI Feng. Values of cytokeratin and Vimentin in diagnosing primary pulmonary sarcomatoid carcinoma and their correlations with clinical prognosis[J]. Journal of Clinical Medicine in Practice, 2020, 24(8): 36-40. DOI: 10.7619/jcmp.202008010
Citation: TAO Huifeng, WU Qingguo, ZHANG Xiaolin, PAN Lei, LI Feng. Values of cytokeratin and Vimentin in diagnosing primary pulmonary sarcomatoid carcinoma and their correlations with clinical prognosis[J]. Journal of Clinical Medicine in Practice, 2020, 24(8): 36-40. DOI: 10.7619/jcmp.202008010

细胞角蛋白及波形蛋白在原发性肺肉瘤样癌中的诊断价值及其与临床预后的关系

基金项目: 

国家科技重大专项项目(2017ZX10305501-008)

详细信息
    通讯作者:

    李锋,E-mail:lifeng@shphc.org.cn

  • 中图分类号: R734.2

Values of cytokeratin and Vimentin in diagnosing primary pulmonary sarcomatoid carcinoma and their correlations with clinical prognosis

  • 摘要: 目的 探讨细胞角蛋白(CK)及波形蛋白(Vimentin)在原发性肺肉瘤样癌(PSC)中的诊断价值及其与临床预后的关系。 方法 选取139例疑似PSC患者为研究组,选取同期30名健康人肺组织标本作为对照组。采用免疫组化法检测肿瘤组织与正常肺组织中CK及Vimentin表达水平。以术后病理诊断为PSC金标准,采用受试者工作曲线(ROC)计算CK及Vimentin诊断PSC的灵敏度、特异性、曲线下面积(AUC)和95%置信区间(95%CI)。对所有PSC患者随访3年,观察PSC患者3年存活率,并采用Cox比例风险回归模型进行多因素分析。 结果 139例疑似PSC患者经术后病理诊断确诊132例, 7例为小细胞肺癌。研究组CK及Vimentin阳性表达率分别为95.68%和97.84%, 对照组CK及Vimentin无阳性表现,差异有统计学意义(P<0.05)。ROC显示, CK诊断PSC的灵敏度、特异性、AUC和95%CI分别为0.985、0.904、0.952和0.899~1.000, Vimentin诊断PSC的灵敏度、特异性、AUC和95%CI分别为1.000、0.919、0.959和0.908~1.000。132例PSC患者1、3年生存率分别为81.06%和56.06%。Cox风险模型分析显示,肿瘤大小、远处转移、CK和Vimentin阳性表达是影响患者3年生存率的风险因素(P<0.05)。 结论 CK和Vimentin在PSC诊断和预后评估中均有一定的临床价值。
    Abstract: Objective To investigate the value of cytokeratin(CK)and Vimentin in diagnosing primary pulmonary sarcomatoid carcinoma(PSC)and their correlations with clinical prognosis. Methods A total of 139 patients with suspected PSC were selected as study group, and samples of normal lung tissues of 30 healthy people were collected as control group. Immunohistochemistry was used to detect the expressions of CK and Vimentin in tumor tissues and normal lung tissues. The postoperative pathological diagnosis was considered as gold standard for PSC, and the sensitivity, specificity, the area under curve(AUC)and 95% confidence interval(95%CI)of CK and Vimentin in the diagnosis of PSC were calculated by the receiver operating curve(ROC). All the patients with PSC were followed up for 3 years, and the 3-year survival rate was observed. Multivariate analysis was carried out by using Cox proportional risk regression model. Results Of the 139 patients with suspected PSC, 132 cases were confirmed by pathological results, and 7 cases were diagnosed as small cell lung cancer. The positive expression rates of CK and Vimentin in the study group were 95.68% and 97.84% respectively, but there was no case with positive expressions of CK and Vimentin in the control group, and there were significant differences in positive expression rates of CK and Vimentin between two groups(P<0.05). ROC showed that the sensitivity, specificity, AUC and 95%CI of CK for diagnosis of PSC were 0.985, 0.904, 0.952 and 0.899 to 1.000 respectively, while those of Vimentin - for diagnosis of PSC were 1.000, 0.919, 0.959 and 0.908 to 1.000 respectively. The 1-year and 3-year survival rates of 132 patients with PSC were 81.06% and 56.06% respectively. Cox risk model analysis showed that tumor size, distant metastasis, positive expressions of CK and Vimentin were risk factors affecting the 3-year survival rate of patients(P<0.05). Conclusion CK and Vimentin have certain clinical values in the diagnosis and prognosis evaluation of PSC.
  • Antoine M, Vieira T, Fallet V, et al. Pulmonary sarcomatoid carcinoma[J]. Ann Pathol, 2016, 36(1): 44-54.

    杨昆, 薛奇. 原发性肺肉瘤样癌临床病理特征及预后87例分析[J]. 中国临床医生杂志, 2019, 47(6): 680-683.
    叶旭燕, 余捷, 潘阿善, 等. 原发性肺肉瘤样癌的CT表现特征[J]. 中国医师进修杂志, 2019, 42(4): 292-295.

    Tamaki T, Shimizu T, Niki M, et al. Immunohistochemical analysis of NANOG expression and epithelial-mesenchymal transition in pulmonary sarcomatoid carcinoma[J]. Oncology letters, 2017, 13(5): 3695-3702.

    何萌萌, 孙伟, 陈静, 等. 细胞角蛋白5/6、P63蛋白、甲状腺转录因子-1、细胞角蛋白7在肺癌组织中的表达及意义[J]. 安徽医药, 2019, 23(5): 903-906

    , 1063.

    谭元元, 武世伍, 柴大敏, 等. 肺肉瘤样癌10例并临床病理分析[J]. 临床与实验病理学杂志, 2016, 32(11): 1287-1289.

    Lin Y, Yang H, Cai Q, et al. Characteristics and Prognostic Analysis of 69 Patients With Pulmonary Sarcomatoid Carcinoma[J]. Am J Clin Oncol, 2016, 39(3): 215-222.

    Zhang B, Wang J, Liu W, et al. Cytokeratin 18 knockdown decreases cell migration and increases chemosensitivity in non-small cell lung cancer[J]. J Cancer Res Clin Oncol, 2016, 142(12): 2479-2487.

    蔡静静, 周永春. 长链非编码RNA尿路上皮癌胚抗原1在实体瘤中的作用和机制[J]. 中国医药, 2019, 14(4): 637-640.
    缪存静, 陈俊杰, 历星, 等. 木犀草素逆转由TGF-β1诱导的人肺癌细胞上皮-间充质转化的实验研究[J]. 中国病理生理杂志, 2019, 35(7): 1163-1168.
    张树伟, 潘亚萍. 病原微生物诱导上皮间充质转化的相关研究进展[J]. 中国微生态学杂志, 2018, 30(2): 240-244.
    付祎婷, 程爱兰. 波形蛋白诱导EMT在肿瘤侵袭转移中的研究进展[J]. 中南医学科学杂志, 2019, 47(1): 89-91

    , 94.

    Jung H, Kim B, Moon B I, et al. Cytokeratin 18 is necessary for initiation of TGF-β1-induced epithelial-mesenchymal transition in breast epithelial cells[J]. Mol Cell Biochem, 2016, 423(1/2): 21-28.

    梁克诚, 甘浪舸, 阮林, 等. 细胞角蛋白表达与Ⅰ期非小细胞肺癌淋巴结微转移相关性研究[J]. 临床肺科杂志, 2014, 19(2): 329-330

    , 342.

    Zhang B, Wang J, Liu W, et al. Cytokeratin 18 knockdown decreases cell migration and increases chemosensitivity in non-small cell lung cancer[J]. J Cancer Res Clin Oncol, 2016, 142(12): 2479-2487.

    郭媛, 徐宏刚, 魏新华, 等. 肺肉瘤样癌的影像学表现及临床病理分析[J]. 中国临床医学影像杂志, 2009, 20(10): 743-745.
    朱莉, 叶剑定, 陈群慧, 等. 肺肉瘤样癌的CT表现与病理分析[J]. 中国医学计算机成像杂志, 2013, 19(2): 124-126.
    张晓莹, 黄平, 孙震, 等. 原发性肺肉瘤样癌18 F-FDG PET/CT影像表现和代谢特点分析[J]. 医学影像学杂志, 2016, 26(12): 2228-2231.
    顾海艇, 周建娅, 吴挺, 等. 肺肉瘤样癌患者的临床特征及预后分析[J]. 中华医学杂志, 2018, 98(10): 744-748.

    Li X, Wang D, Zhao Q, et al. Clinical Significance and Next-Generation Sequencing of Chinese Pulmonary Sarcomatoid Carcinoma[J]. Sci Rep, 2017, 7(1): 3947-3953.

    陈绍森, 邹林, 卢正亮, 等. 血清癌胚抗原水平与免疫组化指标对肺癌患者EGFR基因突变的预测价值[J]. 广东医学, 2018, 39(14): 2200-2203.
    王洪阁. 非小细胞肺癌患者癌胚抗原和细胞角蛋白与表皮生长因子基因突变的关系及靶向治疗的预测价值[J]. 中国老年学杂志, 2019, 39(4): 809-811.

    Luo H T, Liang C X, Luo R C, et al. Identification of relevant prognostic values of cytokeratin 20 and cytokeratin 7 expressions in lung cancer[J]. Biosci Rep, 2017, 37(6): BSR20171086.

  • 期刊类型引用(2)

    1. 李俊,张万青,梁克,符详杰. 手术及靶向治疗肺梭形细胞癌合并腺癌1例. 广东医科大学学报. 2024(01): 118-120 . 百度学术
    2. 惠灿灿,孙艳,吴庆彬,汪艳丽,王芬. 甲状腺肉瘤样癌1例报道. 中国医药导报. 2022(12): 181-184 . 百度学术

    其他类型引用(1)

计量
  • 文章访问数:  525
  • HTML全文浏览量:  104
  • PDF下载量:  7
  • 被引次数: 3
出版历程
  • 收稿日期:  2020-01-12

目录

    /

    返回文章
    返回
    x 关闭 永久关闭